Know Cancer

or
forgot password

A Phase 2 Open-Label Multicenter Study Of The Garft Inhibitor AG2037 In Patients With Metastatic Colorectal Cancer Who Failed Treatment With A 5-Fluorouracil/Leucovorin Regimen.


Phase 2
18 Years
N/A
Not Enrolling
Both
Colorectal Neoplasms

Thank you

Trial Information

A Phase 2 Open-Label Multicenter Study Of The Garft Inhibitor AG2037 In Patients With Metastatic Colorectal Cancer Who Failed Treatment With A 5-Fluorouracil/Leucovorin Regimen.


Inclusion Criteria:



- Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or
rectum

- Stage IV or recurrent disease

- Measurable disease

- Disease progression or recurrence during or after completion of prior first-line
chemotherapy with fluorouracil and leucovorin calcium (5-FU/LV)

- Prior irinotecan or oxaliplatin as part of the 5-FU/LV regimen or as subsequent
therapy allowed

- Only 2 prior regimens for metastatic disease allowed

- One additional regimen as adjuvant therapy allowed provided patient remained
disease-free for > 6 months after completion of therapy*

- Newer, targeted investigational agents (e.g., cetuximab or bevacizumab) are not

counted as a chemotherapeutic regimen unless used in combination with a cytotoxic regimen
NOTE: *If evidence of failure occurred within < 6 months after completion of adjuvant
therapy, patients may have received only 1 additional regimen for metastatic disease

- No active brain metastases (requiring treatment or progressing)

Exclusion Criteria:

- History of blood transfusion within 14 days

- Need of concurrent Administration of allopurinol

- History of Radiotherapy or Chemotherapy within 4 weeks

- Any psychological or sociological condition, addidtive disorder or family problems
that might preclude compliance with the protocol

- Any unstable or severe intercurrent medical condition that in the opinion of th
einvestigator might interfere with achievement of study objectives

- Receipt of an investigational agent within 28 days prior to first day of dosing with
AG-2037

- Pregnant or breast feeding

- Previous treatment with GARFT inhibitors

- History of a malignancy (other than colorectal cancer) excpet those treated with
curative intent for skin cancer (other than melanoma) or in situ breast or cervical
cancer or those treated with curative intent for any other cancer with no evidence of
disease for 5 years

- Active brain metastases (requiring treatment or progression)

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the overall objective response rate (complete and partial responses) of AG-2037 in patients with metastatic colorectal cancer who failed treatment with 5FU/LV regimen and up to one other chemotherapeutic regimen.

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A4371004

NCT ID:

NCT00078468

Start Date:

December 2003

Completion Date:

September 2004

Related Keywords:

  • Colorectal Neoplasms
  • Neoplasms
  • Colorectal Neoplasms

Name

Location

Pfizer Investigational SiteBlendora, California  91740
Pfizer Investigational SiteBronx, New York  10461
Pfizer Investigational SiteClearwater, Florida  33761
Pfizer Investigational SiteWashington, District of Columbia  20007-2197